Tema Cardiovascular and Metabolic ETF (HRTS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tema Cardiovascular and Metabolic ETF (HRTS) with AI Score 47/100 (Weak). The Tema Heart & Health ETF (HRTS) focuses on investing in companies poised to benefit from advancements in biotechnology and healthcare, particularly those involved in cardiology, metabolic diseases, and weight loss therapies. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 16, 2026Tema Cardiovascular and Metabolic ETF (HRTS) Financial Services Profile
Tema Heart & Health ETF (HRTS) is an exchange-traded fund targeting companies involved in cardiology, metabolic diseases, and weight loss therapies. With a market cap of $0.06 billion and a beta of 0.91, HRTS offers investors a focused approach to capitalize on advancements in the biotechnology and healthcare sectors related to heart and metabolic health.
Investment Thesis
The Tema Heart & Health ETF (HRTS) presents a focused investment opportunity within the healthcare sector, targeting companies involved in cardiology, metabolic diseases, and weight loss therapies. With a beta of 0.91, HRTS exhibits market sensitivity. The increasing prevalence of cardiovascular and metabolic diseases, coupled with advancements in biotechnology, creates a favorable backdrop for the ETF's holdings. Key value drivers include the growing demand for innovative treatments and therapies, as well as the potential for regulatory approvals and market expansion. However, investors may want to evaluate the risks associated with the healthcare sector, such as clinical trial failures, regulatory hurdles, and competitive pressures. The absence of a dividend yield may deter some income-seeking investors, but the fund's potential for capital appreciation could offset this drawback.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.06 billion indicates a relatively small size, offering potential for high growth but also increased volatility.
- Beta of 0.91 suggests that HRTS's price is slightly less volatile than the overall market.
- Focus on cardiology, metabolic diseases, and weight loss therapies provides targeted exposure to specific growth areas within the healthcare sector.
- Absence of dividend yield may appeal more to growth-oriented investors than income-focused ones.
- The fund's performance is closely tied to the success of its underlying holdings in the biotechnology and healthcare industries.
Competitors & Peers
Strengths
- Targeted exposure to high-growth areas within the healthcare sector.
- Potential to benefit from advancements in biotechnology and medical technology.
- Diversification across multiple companies involved in cardiology, metabolic diseases, and weight loss therapies.
Weaknesses
- Concentrated focus may lead to higher volatility compared to broader healthcare ETFs.
- Performance is highly dependent on the success of its underlying holdings.
- Absence of dividend yield may deter some income-seeking investors.
Catalysts
- Upcoming: Positive clinical trial results for portfolio companies developing new treatments for cardiovascular and metabolic diseases.
- Ongoing: Increasing adoption of telemedicine and remote patient monitoring technologies.
- Ongoing: Government initiatives and funding programs supporting research and development in the healthcare sector.
- Ongoing: Rising awareness of the importance of preventive care and early detection of cardiovascular and metabolic diseases.
Risks
- Potential: Regulatory changes and healthcare reforms can impact the profitability of portfolio companies.
- Potential: Economic downturns can reduce healthcare spending and impact demand for treatments and therapies.
- Potential: Competition from generic drugs and biosimilars can erode the market share of branded products.
- Ongoing: Clinical trial failures and regulatory setbacks can negatively impact portfolio companies.
- Ongoing: Market volatility and fluctuations in investor sentiment can impact the ETF's performance.
Growth Opportunities
- Advancements in Biotechnology: The rapid pace of innovation in biotechnology presents a significant growth opportunity for HRTS. As new therapies and technologies emerge for treating cardiovascular and metabolic diseases, companies within the ETF's portfolio stand to benefit. The global biotechnology market is projected to reach $1.5 trillion by 2028, growing at a CAGR of 12.3% from 2021 to 2028. This growth is driven by increasing investments in research and development, as well as the rising demand for personalized medicine and gene therapies. Timeline: Ongoing.
- Increasing Prevalence of Metabolic Diseases: The rising prevalence of metabolic diseases, such as diabetes and obesity, is driving demand for new treatments and therapies. HRTS is well-positioned to capitalize on this trend by investing in companies that are developing innovative solutions for managing these conditions. The global metabolic diseases market is expected to reach $150 billion by 2025, growing at a CAGR of 7.5% from 2020 to 2025. This growth is fueled by the increasing awareness of metabolic disorders and the growing need for effective treatment options. Timeline: Ongoing.
- Growing Demand for Weight Loss Therapies: The increasing prevalence of obesity and related health conditions is driving demand for weight loss therapies. HRTS invests in companies that are developing innovative solutions for weight management, including pharmaceuticals, medical devices, and lifestyle interventions. The global weight loss market is projected to reach $427.3 billion by 2030, growing at a CAGR of 7.6% from 2021 to 2030. This growth is driven by the increasing awareness of the health risks associated with obesity and the growing demand for safe and effective weight loss solutions. Timeline: Ongoing.
- Expansion into Emerging Markets: Emerging markets represent a significant growth opportunity for HRTS. As healthcare infrastructure improves and access to medical care expands in these regions, the demand for treatments and therapies for cardiovascular and metabolic diseases is expected to increase. The emerging markets healthcare sector is projected to grow at a CAGR of 9.8% from 2021 to 2028, driven by factors such as rising incomes, increasing urbanization, and growing awareness of health issues. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Companies within HRTS's portfolio may pursue strategic partnerships and acquisitions to expand their product offerings, enter new markets, and gain access to new technologies. These deals can create significant value for shareholders and drive growth for the ETF. The healthcare industry is characterized by a high level of M&A activity, with companies constantly seeking to consolidate their positions and enhance their competitive advantages. Timeline: Ongoing.
Opportunities
- Increasing prevalence of cardiovascular and metabolic diseases driving demand for new treatments and therapies.
- Expansion into emerging markets with growing healthcare infrastructure.
- Potential for strategic partnerships and acquisitions to enhance portfolio companies' growth prospects.
Threats
- Regulatory hurdles and clinical trial failures can negatively impact portfolio companies.
- Competition from other healthcare ETFs and mutual funds.
- Economic downturns can reduce healthcare spending and impact demand for treatments and therapies.
Competitive Advantages
- Specialized Focus: HRTS's focus on cardiology, metabolic diseases, and weight loss therapies provides a differentiated offering compared to broader healthcare ETFs.
- Expertise: The fund's management team has expertise in the healthcare sector and a deep understanding of the market dynamics driving growth in these specific areas.
- Brand Recognition: HRTS benefits from the Tema brand, which is known for its expertise in thematic investing.
About HRTS
The Tema Heart & Health ETF (HRTS) is designed to provide investors with exposure to companies at the forefront of addressing cardiovascular and metabolic diseases, as well as weight loss therapies. This ETF strategically invests in companies that are expected to benefit from the ongoing advancements in biotechnology and healthcare. HRTS focuses on a specific niche within the broader healthcare sector, aiming to capture the growth potential of companies developing innovative solutions for heart health, metabolic disorders, and obesity. The fund's investment strategy involves identifying and selecting companies that are actively involved in research, development, and commercialization of products and services related to cardiology, metabolic diseases, and weight management. By concentrating on these specific areas, HRTS offers a targeted approach for investors seeking to capitalize on the increasing prevalence of these health conditions and the growing demand for effective treatments and therapies. The ETF's holdings may include pharmaceutical companies, medical device manufacturers, biotechnology firms, and healthcare service providers that are dedicated to improving patient outcomes in these critical areas of health.
What They Do
- Invests in companies involved in cardiology.
- Targets companies focused on metabolic diseases.
- Includes companies that develop weight loss therapies.
- Seeks to benefit from advances in biotechnology and healthcare.
- Provides exposure to the growing market for cardiovascular and metabolic health solutions.
- Offers a targeted approach for investors seeking to capitalize on specific areas within the healthcare sector.
Business Model
- HRTS generates revenue through management fees charged to investors.
- The ETF's performance is directly linked to the performance of its underlying holdings.
- The fund's investment strategy focuses on identifying and selecting companies with strong growth potential in the cardiology, metabolic diseases, and weight loss therapies markets.
Industry Context
The Tema Heart & Health ETF (HRTS) operates within the asset management industry, focusing specifically on the healthcare sector. The global healthcare market is experiencing substantial growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. The ETF's focus on cardiology, metabolic diseases, and weight loss therapies aligns with key trends in the healthcare industry, as these areas represent significant unmet needs and opportunities for innovation. The competitive landscape includes other healthcare-focused ETFs and mutual funds, but HRTS differentiates itself through its targeted approach to heart and metabolic health.
Key Customers
- Retail investors seeking exposure to the healthcare sector.
- Institutional investors looking for targeted investments in cardiology, metabolic diseases, and weight loss therapies.
- Financial advisors seeking to diversify client portfolios with healthcare-focused ETFs.
Financials
Chart & Info
Tema Cardiovascular and Metabolic ETF (HRTS) stock price: Price data unavailable
Latest News
-
'Roche Restricts Consulting Work With Big Four Firms To Cut Costs' - Bloomberg
benzinga · Mar 24, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HRTS.
Price Targets
Wall Street price target analysis for HRTS.
MoonshotScore
What does this score mean?
The MoonshotScore rates HRTS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Tema Cardiovascular and Metabolic ETF Stock: Key Questions Answered
What does Tema Cardiovascular and Metabolic ETF do?
The Tema Heart & Health ETF (HRTS) is an exchange-traded fund that invests in companies poised to benefit from advancements in biotechnology and healthcare, specifically those involved in cardiology, metabolic diseases, and weight loss therapies. The fund aims to provide investors with targeted exposure to the growing market for cardiovascular and metabolic health solutions by investing in companies that develop innovative treatments, therapies, and technologies. HRTS offers a focused approach to capitalize on the increasing prevalence of these health conditions and the growing demand for effective treatments.
What do analysts say about HRTS stock?
AI analysis is currently pending for HRTS, so there is no analyst consensus available at this time. Investors should conduct their own due diligence and consider the fund's investment strategy, risk factors, and potential growth opportunities before making any investment decisions. Key valuation metrics to consider include the fund's price-to-earnings ratio, price-to-book ratio, and dividend yield (if any). Growth considerations include the fund's exposure to high-growth areas within the healthcare sector and its ability to capitalize on advancements in biotechnology and medical technology.
What are the main risks for HRTS?
The main risks for HRTS include regulatory hurdles and clinical trial failures, which can negatively impact portfolio companies. Economic downturns can reduce healthcare spending and impact demand for treatments and therapies. Competition from generic drugs and biosimilars can erode the market share of branded products. Market volatility and fluctuations in investor sentiment can impact the ETF's performance. Investors should also consider the risks associated with investing in the healthcare sector, such as product liability lawsuits and intellectual property disputes. The fund's concentrated focus may lead to higher volatility compared to broader healthcare ETFs.
How does Tema Cardiovascular and Metabolic ETF generate revenue in the financial services sector?
Tema Cardiovascular and Metabolic ETF (HRTS) generates revenue primarily through management fees. These fees are charged to investors as a percentage of the assets under management (AUM). The ETF's revenue is directly correlated to its AUM; therefore, attracting and retaining investor capital is crucial. The management fee covers the costs associated with managing the fund, including research, trading, administration, and marketing. The ETF's profitability depends on its ability to efficiently manage expenses and maintain a competitive fee structure while delivering attractive returns to investors.
What is Tema Cardiovascular and Metabolic ETF's approach to managing risk in its investment portfolio?
Tema Cardiovascular and Metabolic ETF (HRTS) manages risk through diversification within its targeted investment universe of companies involved in cardiology, metabolic diseases, and weight loss therapies. The fund's investment strategy involves selecting companies with strong growth potential and attractive valuations, while also considering factors such as regulatory risks, clinical trial outcomes, and competitive pressures. The fund's management team actively monitors the portfolio and makes adjustments as needed to mitigate risks and capitalize on opportunities. However, investors should be aware that the fund's concentrated focus may lead to higher volatility compared to broader healthcare ETFs.
What are the key factors to evaluate for HRTS?
Tema Cardiovascular and Metabolic ETF (HRTS) currently holds an AI score of 47/100, indicating low score. Key strength: Targeted exposure to high-growth areas within the healthcare sector.. Primary risk to monitor: Potential: Regulatory changes and healthcare reforms can impact the profitability of portfolio companies.. This is not financial advice.
How frequently does HRTS data refresh on this page?
HRTS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HRTS's recent stock price performance?
Recent price movement in Tema Cardiovascular and Metabolic ETF (HRTS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted exposure to high-growth areas within the healthcare sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, limiting the depth of financial insights.
- Market data is as of 2026-03-16 and may not reflect current conditions.